Craighead I B, Heys S D, Smart L M, Thomson A W, Whiting P H
Department of Pathology, University of Aberdeen, Foresterhill, U.K.
Immunopharmacology. 1990 Jul-Aug;20(1):21-9. doi: 10.1016/0162-3109(90)90004-x.
The toxicity of cyclosporin A (CsA) formulated in either olive oil (OO) or fish muscle oil (FO) was investigated in groups of normal Sprague-Dawley rats or in animals which had undergone laparotomy or unilateral nephrectomy. CsA (25 mg/kg/day for 14 days) was administered by gavage from the time of operation, and indices of renal and hepatic function were determined at regular intervals. Urinary thromboxane B2 (TxB2) excretion and whole blood CsA concentrations were determined on day 14, when renal histology was also examined. Compared to CsA/OO treatment, and observed only in normal animals, body weight was significantly increased following administration of CsA/FO, to values similar to those observed following treatment with FO alone. Although there was evidence of renal dysfunction in all CsA-treated animals, irrespective of drug vehicle, elevations in plasma urea and urinary N-acetyl-beta-D-glucosaminidase activity were significantly more pronounced in rats given CsA/OO compared with CsA/FO. Indeed, compared with pretreatment values, no significant changes in these parameters were observed in CsA/FO-treated nephrectomized animals. Whilst there were no great differences in plasma creatinine or creatinine clearance rates between CsA/OO- and CsA/FO-treated groups, animals given CsA/FO showed less evidence of renal structural change as assessed by proximal tubular cell vacuolation, basophilia and microcalcification. The extent of hepatic impairment was also significantly less pronounced when FO was used as drug vehicle. Groups of CsA/FO-treated animals also demonstrated significantly lower whole blood CsA levels compared with CsA/OO groups; moreover, TxB2 excretion was significantly lower in the former group.(ABSTRACT TRUNCATED AT 250 WORDS)
在正常的斯普拉格-道利大鼠组或接受过剖腹手术或单侧肾切除术的动物中,研究了用橄榄油(OO)或鱼肌肉油(FO)配制的环孢素A(CsA)的毒性。从手术时开始通过灌胃给予CsA(25mg/kg/天,持续14天),并定期测定肾功能和肝功能指标。在第14天测定尿血栓素B2(TxB2)排泄量和全血CsA浓度,同时检查肾脏组织学。与CsA/OO治疗相比,仅在正常动物中观察到,给予CsA/FO后体重显著增加,达到与单独用FO治疗后观察到的值相似。尽管在所有接受CsA治疗的动物中都有肾功能障碍的证据,无论药物载体如何,但与CsA/FO相比,给予CsA/OO的大鼠血浆尿素和尿N-乙酰-β-D-氨基葡萄糖苷酶活性的升高更为明显。事实上,与预处理值相比,在接受CsA/FO治疗的肾切除动物中,这些参数没有显著变化。虽然CsA/OO组和CsA/FO组之间的血浆肌酐或肌酐清除率没有很大差异,但通过近端肾小管细胞空泡化、嗜碱性和微钙化评估,给予CsA/FO的动物肾脏结构变化的证据较少。当使用FO作为药物载体时,肝损伤的程度也明显较轻。与CsA/OO组相比,CsA/FO治疗的动物组全血CsA水平也显著较低;此外,前一组的TxB2排泄显著较低。(摘要截短为250字)